23 research outputs found
Potential direct secondary care cost benefits of HealthyWeightHub - Virtual Hospital 2.0 digital lifestyle intervention
Peer reviewe
Economic Value of Adjunctive Brivaracetam Treatment Strategy for Focal Onset Seizures in Finland
Impact of Alzheimer's disease on the family caregiver's long-term quality of life: results from an ALSOVA follow-up study
Peer reviewe
Low vision status and declining vision decrease Health-Related Quality of Life : Results from a nationwide 11-year follow-up study
Evaluating health status and quality of life in outcomes research. A review of the 15D HRQOL - instrument\'s practical properties
Marginal effects of FINDRISC items and other covariates on the SF-6D HRQoL index.
<p>Marginal effects of FINDRISC items and other covariates on the SF-6D HRQoL index.</p
The characteristics of the participants across the diabetes risk (FINDRISC) categories.
<p>The characteristics of the participants across the diabetes risk (FINDRISC) categories.</p
Mean observed HRQoL (15D) dimension values in relation to the FINDRISC score.
<p>Linear trends were fitted to data using ordinary least squares regression. The corresponding variance was estimated using a bootstrap procedure with 1,000 replications. HRQoL: Health-related quality of life. FINDRISC: Finnish Diabetes Risk Score.</p
Observed mean HRQoL index values and fitted linear trends (95% CI) in relation to the FINDRISC scores.
<p>Linear trends were fitted to data using Tobit regression. The corresponding variance was estimated using a bootstrap procedure with 1,000 replications.*Adjusted for sex, employment and cohabiting. HRQoL: Health-related quality of life. FINDRISC: Finnish Diabetes Risk Score.</p
The Progression of Alzheimer's Disease Can Be Assessed with a Short Version of the CERAD Neuropsychological Battery: The Kuopio ALSOVA Study
Background/Aims: Measuring and predicting Alzheimer's disease (AD) progression is important in order to adjust treatment and allocate care resources. We aimed to identify a combination of subtests from the Consortium to Establish a Registry for Alzheimer's Disease Neuropsychological Battery (CERAD-NB) that best correlated with AD progression in follow-up as well as to predict AD progression. Method: A total of 236 participants with very mild [Clinical Dementia Rating (CDR) = 0.5] or mild AD (CDR = 1.0) at baseline were followed up for 3 years. The CERAD-NB and Mini-Mental State Examination (MMSE) were used to assess cognition, and the CDR scale sum of boxes (CDR-sb) was employed to evaluate AD progression. Generalized estimating equations were used to develop models to predict and follow up disease progression. Results: Performance declined on all CERAD-NB subtests. The ability of the separate subtests to distinguish between groups (baseline CDR = 0.5 or 1.0) diminished during follow-up. The best combination of subtests that explained 62% of CDR-sb variance in follow-up included verbal fluency, constructional praxis, the clock drawing test, and the MMSE. Baseline values of the same combination predicted 37% of the CDR-sb change. Conclusion: A short version of the CERAD-NB subtests provides a promising and time-efficient alternative for measuring cognitive deterioration during AD follow-up. Although the initial signs of AD include memory difficulties, it may be useful to assess non-memory tasks in follow-up